Search results
Mar 6, 2018 · Among patients with Gleason score 9-10 prostate cancer, treatment with EBRT+BT with androgen deprivation therapy was associated with significantly better prostate cancer–specific mortality and longer time to distant metastasis compared with EBRT with androgen deprivation therapy or with radical prostatectomy.
Apr 26, 2021 · The current clinical disease staging methods regarded patients with GS 9–10 PCa as an independent group from patients with other GS and assumed that patients with GS 9–10 PCa undergo similar risks of recurrence, metastasis, and mortality . However, different Gleason patterns (GP), GP 4 + 5 and 5 + 4, can both lead to GS 9.
Nov 1, 2020 · We pairwise compared the overall death risk and cancer‐specific death risk between subgroups of PCa patients with Gleason 7, 8, and 9–10 after PSM adjusted, and found that patients with Gleason 5 + 3 did have higher overall death and cancer‐specific death than patients with Gleason 3 + 5 (OS: HR = 1.26, p = 0.042; CSS: HR = 1.42, p = 0. ...
Nov 1, 2022 · Under the Gleason Score system, a 6 is considered low grade, 7 is intermediate and scores of 8, 9, or 10 are considered high-grade cancers. The higher the Gleason score, the more likely it is the prostate cancer will grow and spread quickly.
We showed that radiation-based treatments and surgery, with contemporary standards, offer equivalent survival for patients with very aggressive cancers (defined as Gleason score 9-10).
Nov 3, 2018 · Investigators at 12 hospitals in the United States and Norway compared the clinical outcomes of 1,809 men with Gleason score 9-10 prostate cancer after they had either radical prostatectomy, external-beam radiation therapy (EBRT) with androgen deprivation therapy (ADT), or EBRT plus a brachytherapy “boost” with ADT; the men were treated ...
Aug 2, 2016 · Radiation therapy and radical prostatectomy (RP) offer men with Gleason score 9–10 prostate cancer (PCa) equivalent cancer-specific and overall survival, according to a new study.
Prostate-cancer specific mortality (PCSM) was defined based on either clinical documentation or inclusion of CaP as a primary cause of death on a death certificate. One-hundred-and-two out of 107 patients who were deceased at last follow-up (95.3%) had either form of PCSM determination available.
Therefore, we investigated whether treatment of Gleason score 9-10 prostate cancer with RP and adjuvant EBRT, ADT, or MaxRP vs MaxRT was associated with PCSM and all-cause mortality (ACM) risk.
The risks of prostate cancer death for men with Gleason scores 4 + 5, 5 + 4, and 5 + 5 at 10 yr of follow-up were 0.45 (confidence interval [CI] 0.44-0.46), 0.56 (0.55-0.58), and 0.66 (0.63-0.68), respectively.
